De Novo device
Dexcom G6 Continuous Glucose Monitoring (CGM) System
Dexcom, Inc. · Integrated Continuous Glucose Monitoring System, Factory Calibrated (QBJ, Class II) · First FDA decision Mar 27, 2018, newest Jan 11, 2023Diabetes
Last checked: Nov 19, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
7
De Novo pathway
Device trials
171
Naming "Dexcom G6"
MAUDE reports
1,352,453
Brand "Dexcom G6", since 2015
PubMed studies
272
Mentioning "Dexcom G6"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing Dexcom G6 Continuous Glucose Monitoring (CGM) System
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 6 of 7 decisions filed under this name.
K223931 · Decided Jan 11, 2023 · 12 days after receipt
Device type: Integrated Continuous Glucose Monitoring System, Factory Calibrated (QBJ) · Laboratory Medicine & Pathology
K221259 · Decided Jul 29, 2022 · 88 days after receipt
Device type: Integrated Continuous Glucose Monitoring System, Factory Calibrated (QBJ) · Laboratory Medicine & Pathology
K201328 · Decided Jul 15, 2021 · 422 days after receipt
Device type: Integrated Continuous Glucose Monitoring System, Factory Calibrated (QBJ) · Laboratory Medicine & Pathology
3 more FDA decisions with a free account
Older decisions: DEN170088
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
- Implantable Continuous Glucose Monitors (I-CGM)Local determinationIn effectL38662CGS Administrators, LLCUpdated Sep 29, 2026
- Implantable Continuous Glucose Monitors (I-CGM)Local determinationIn effectL38623Wellpoint FederalUpdated Jul 14, 2026
- Implantable Continuous Glucose Monitors (I-CGM)Local determinationIn effectL38686WPS Insurance CorporationUpdated Jun 18, 2026
- Implantable Continuous Glucose Monitors (I-CGM)Local determinationIn effectL38657Noridian Healthcare Solutions, LLCUpdated Oct 14, 2025
- Home Health Plans of Care: Monitoring Glucose Control in the Medicare Home Health Population with Type II Diabetes MellitusLocal determinationIn effectL35132Palmetto GBAUpdated Apr 9, 2025
- Implantable Continuous Glucose Monitors (I-CGM)Local determinationIn effectL38743Palmetto GBAUpdated Jul 19, 2024
- Implantable Continuous Glucose Monitors (I-CGM)Local determinationIn effectL38664First Coast Service Options, Inc.Updated Jun 21, 2024
- Implantable Continuous Glucose Monitors (I-CGM)Local determinationIn effectL38617Novitas Solutions, Inc.Updated Jun 21, 2024
Clinical trials
Device studies on ClinicalTrials.gov that name "Dexcom G6", any status and sponsor, newest update first.
- Interventional Clinical Trial Evaluating COVER PATCH CAPTEUR PROTECT Support Solutions for Continuous Glucose Monitoring Sensors in Patients With DiabetesPivotal-lookingRecruiting
CAPTEUR PROTECTNot on our public-company list
NCT07018180 · 194 participants (planned) · Start Dec 5, 2025
Device: Use of COVER patchs for continuous glucose monitoring sensor · For: Diabetes
Sites: Bron, France; Corbeil-Essonnes, France; Grenoble, France · 10 sites in all
- Wearable Technology to Evaluate Hyperglycemia and HRV in DMD - Longitudinal AimActive, not recruiting
Vanderbilt University Medical CenterAcademic, hospital or other
NCT06093100 · 10 participants (planned) · Start Jul 10, 2024 · Primary completion Dec 2029
Device: wearable technology · For: Duchenne Muscular Dystrophy
Sites: Nashville, Tennessee
- Outpatient Pramlintide StudyNot yet recruiting
Oregon Health and Science UniversityAcademic, hospital or other
NCT07914621 · 26 participants (planned) · Start Nov 2, 2026 · Primary completion Jan 31, 2027
Device: Single-hormone automated insulin delivery system; Dual-hormone automated insulin and pramlintide delivery system · For: Type 1 Diabetes
168 more trials with a free account
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "Dexcom G6", and for the whole product code for context.
This brand
1,352,453 reports: 1,339,342 malfunction, 13,018 injury, 67 death
Whole product code QBJ
2,390,871 reports: 2,344,654 malfunction, 45,370 injury, 256 death
Newest reports for this brand
3004753838-2026-289473 · Received Oct 30, 2026 · Event dated Jun 15, 2026
Device type: Integrated Continuous Glucose Monitoring System, Factory Calibrated (QBJ)
Device problem as coded: No Device Output
Patient problem as coded: No Clinical Signs, Symptoms or Conditions
3004753838-2026-289465 · Received Oct 30, 2026 · Event dated Jun 25, 2026
Device type: Integrated Continuous Glucose Monitoring System, Factory Calibrated (QBJ)
Device problem as coded: No Device Output
Patient problem as coded: No Clinical Signs, Symptoms or Conditions
3004753838-2026-289474 · Received Oct 30, 2026 · Event dated Oct 14, 2026
Device type: Integrated Continuous Glucose Monitoring System, Factory Calibrated (QBJ)
Device problem as coded: Wireless Communication Problem
Patient problem as coded: No Clinical Signs, Symptoms or Conditions
2 more reports with a free account
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
Z-0318-2026 · Started Aug 28, 2025 · Posted by FDA Oct 30, 2025
Reason given: A software defect in version v1.15.0 of the G6 Android app can cause the app to terminate unexpectedly, which may result in the user not receiving estimated glucose values, alarms, alerts or notifications. This could result in the missed detection of a hyperglycemic or hypoglycemic event, protentional resulting in...
Cause as FDA categorized it: Software Design Change · Device type: Integrated Continuous Glucose Monitoring System, Factory Calibrated (QBJ)
- Dexcom G6 Glucose Receiver, SKUs (Part Number): STK-FM-001 (MT27408-1) & STK-FR-001 (MT27408-1)Open, Classified
Z-1943-2025 · Started May 12, 2025 · Posted by FDA Jun 16, 2025
Reason given: Defective foam or an assembly error may cause the receiver speaker to lose contact with the printed circuit board, leading to missed audible alerts for low or high blood glucose values. A missed audible alert for low or high blood glucose values could lead to untreated hypo or hyperglycemia which can cause seizures,...
Cause as FDA categorized it: Nonconforming Material/Component · Device type: Integrated Continuous Glucose Monitoring System, Factory Calibrated (QBJ)
- Dexcom G6, Continuous Glucose Monitoring System, REFs: STK-OM-001, STR-OM-001, STR-OR-001Open, Classified
Z-1202-2025 · Started Jan 27, 2025 · Posted by FDA Feb 20, 2025
Reason given: Under very rare situations, the Dexcom G6 touchscreen receiver may not provide high or low glucose alarms/alerts as designed, which can result in two different conditions. First, if a receiver operating system .net error occurs when an alarm/alert should be triggered, the initial alarm/alert will not be delivered...
Cause as FDA categorized it: Software design · Device type: Integrated Continuous Glucose Monitoring System, Factory Calibrated (QBJ)
5 more recall records with a free account
Published research
The most relevant PubMed records for "Dexcom G6"[tiab]. The summary above synthesizes these.
- Continuous glucose monitoring (Dexcom g6) in people with diabetes after kidney transplantation.
Jakubowska Z, Mayszko J · Ren Fail · 2024
- Performance of the Dexcom G6 Continuous Glucose Monitoring System During Cardiac Surgery Using Hypothermic Extracorporeal Circulation.
Herzig D, Vettoretti M, Guensch DP, et al. · Diabetes Care · 2023Research Support, Non-U.S. Gov't
- Continuous Glucose Monitoring Profiles in Healthy Nondiabetic Participants: A Multicenter Prospective Study.
Shah VN, DuBose SN, Li Z, et al. · J Clin Endocrinol Metab · 2019Multicenter Study, Research Support, Non-U.S. Gov't
- Continuous Glucose Monitoring Profiles in Pregnancies With and Without Gestational Diabetes Mellitus.
Durnwald C, Beck RW, Li Z, et al. · Diabetes Care · 2024Observational Study, Research Support, Non-U.S. Gov't
- Performance of the Dexcom G6 Continuous Glucose Monitoring System in Pregnant Women with Diabetes.
Castorino K, Polsky S, O'Malley G, et al. · Diabetes Technol Ther · 2020Research Support, Non-U.S. Gov't
- Cost-utility analysis of Dexcom G6 real-time continuous glucose monitoring versus FreeStyle Libre 1 intermittently scanned continuous glucose monitoring in adults with type 1 diabetes in Belgium.
Visser MM, Van Muylder A, Charleer S, et al. · Diabetologia · 2024Research Support, Non-U.S. Gov't
- Continuous Glucose Monitoring-Guided Insulin Administration in Hospitalized Patients With Diabetes: A Randomized Clinical Trial.
Spanakis EK, Urrutia A, Galindo RJ, et al. · Diabetes Care · 2022Randomized Controlled Trial, Research Support, N.I.H., Extramural
- Contact allergy to the Dexcom G6 glucose monitoring system-Role of 2,2'-methylenebis(6-tert-butyl-4-methylphenol) monoacrylate in the new adhesive.
Oppel E, Högg C, Oschmann A, et al. · Contact Dermatitis · 2022
- Accuracy of Dexcom G6 Continuous Glucose Monitoring in Non-Critically Ill Hospitalized Patients With Diabetes.
Davis GM, Spanakis EK, Migdal AL, et al. · Diabetes Care · 2021Research Support, N.I.H., Extramural, Research Support, U.S. Gov't, Non-P.H.S.
- Reliability of the Dexcom G6 Continuous Glucose Monitor During Hyperbaric Oxygen Exposure.
Huang E, Demirel S, Bliss C, et al. · Diabetes Technol Ther · 2020Research Support, Non-U.S. Gov't
- A Modified CGM Algorithm Enhances Data Availability While Retaining iCGM Performance.
Harvey Towers RA, Zhang X, Yousefi R, et al. · J Diabetes Sci Technol · 2022Research Support, Non-U.S. Gov't
- Real-Time Continuous Glucose Monitoring in Pregnancies With Gestational Diabetes Mellitus: A Randomized Controlled Trial.
Valent AM, Rickert M, Pagan CH, et al. · Diabetes Care · 2025Randomized Controlled Trial
Other devices of this type
Also filed under product code QBJ.
- Dexcom G7 Continuous Glucose Monitoring SystemDexcom, Inc. · 510(k) 2026
- FreeStyle Libre 3 Continuous Glucose Monitoring SystemAbbott Diabetes Care, Inc. · 510(k) 2024
- Dexcom G7 15 Day Continuous Glucose Monitoring SystemDexcom, Inc. · 510(k) 2025
- FreeStyle Libre 2 Flash Glucose Monitoring SystemAbbott Diabetes Care, Inc. · 510(k) 2023
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.